Abstract Title:

The risk of cumulative renal effects of intravenous bisphosphonates.

Abstract Source:

Support Cancer Ther. 2006 Jan 1;3(2):77-83. PMID: 18632443

Abstract Author(s):

Jean-Jacques Body

Article Affiliation:

Department of Internal Medicine, Institut Jules Bordet, Université Libré de Bruxelles, Belgium.


Some level of renal dysfunction is common in patients with cancer. This could be a result of an age-related kidney function decrease, the underlying disease (eg, multiple myeloma), or the effects of nephrotoxic medications. Some intravenous (I.V.) bisphosphonates have been associated with occasional renal toxicity in the clinical setting. Therefore, the choice of an I.V. bisphosphonate should take into account the risk of renal deterioration. Preclinical studies also suggest that there might be considerable differences between the renal safety profiles of commonly used I.V. bisphosphonates. Variations in the risk of histopathologic damage and the ability to cause cumulative toxicity have been observed in comparative preclinical studies of I.V. bisphosphonates. The reasons for these apparent differences are not fully understood. Research shows that renal safety profiles might be influenced by pharmacokinetic properties, such as renal tissue half-life, protein binding, and intracellular potency. Preclinical analyses are warranted in order to confirm and evaluate these differences between bisphosphonates.

Study Type : Commentary
Additional Links

Print Options

Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2021 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.